Paratek Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Paratek Pharmaceuticals

17/05/2021 14:33

* Paratek Pharmaceuticals Inc  PRTK.OQ  reported a quarterly
adjusted loss of 39 cents​​ per share for the quarter ended
in March. The mean expectation of five analysts for the quarter
was for a loss of 38 cents per share.
* Revenue rose 107.4% to $16.43 million from a year ago; 
analysts expected $28.72 million. 
* Paratek Pharmaceuticals Inc's reported EPS for the quarter was
a loss of 39 cents​.
* The mean earnings estimate of analysts had fallen by
about 179.5% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Paratek Pharmaceuticals Inc shares had risen by 7.6% this
quarter and gained 21.4% so far this year.
* The company reported a quarterly loss of $18.35 million.
* Wall Street's median 12-month price target for Paratek
Pharmaceuticals Inc is $15.00 
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
This summary was machine generated May 17 at 01:32 p.m. GMT.
​All figures in US dollars